

1 **Predictors of unfavourable treatment outcome in patients diagnosed with drug-resistant**
2 **tuberculosis in the Torres Strait / Papua New Guinea border region**

3 J'Belle Foster,^{1,2,3,#a}, Diana Mendez,³, Ben J. Marais⁴, Dunstan Peniyamina⁵, Emma S. McBryde^{1,2,3,#a}

4

5 ¹James Cook University College of Medicine and Dentistry, Townsville, Queensland, Australia

6 ²Torres and Cape Tuberculosis Control Unit, Thursday Island, Queensland, Australia

7 ³Australian Institute of Tropical Health and Medicine, Townsville, Queensland, Australia

8 ⁴Sydney Institute for Infectious Diseases and Biosecurity, Westmead, New South Wales, Australia

9 ⁵Cairns Tropical Public Health Service, Cairns, Queensland, Australia

10 #aCurrent address: James Cook University College of Medicine and Dentistry, Townsville,
11 Queensland, Australia

12

13 **ABSTRACT**

14 Drug-resistant tuberculosis (DR-TB) is an ongoing challenge in the Torres Strait Islands (TSI) / Papua
15 New Guinea (PNG) border region. Treatment success rates have historically been poor for patients
16 diagnosed with DR-TB, leading to increased transmission. This study aimed to identify variables
17 associated with unfavourable outcome in patients diagnosed with DR-TB to inform programmatic
18 improvements.

19 A retrospective study of all DR-TB cases who presented to Australian health facilities in the Torres
20 Strait between 1 March 2000 and 31 March 2020 was performed. This time period covers four
21 distinct TB programmatic approaches which reflect Australian and Queensland Government
22 decisions on TB management in this remote region. Univariate and multivariate predictors of
23 unfavourable outcome were analysed. Unfavourable outcome was defined as lost to follow up,
24 treatment failure and death. Successful outcome was defined as cure and treatment completion.

25 In total, 133 patients with resistance to at least one TB drug were identified. The vast majority
26 (123/133; 92%) of DR-TB patients had pulmonary involvement; and of these, 41% (50/123) had both
27 pulmonary and extrapulmonary TB. Unfavourable outcomes were observed in 29% (39/133) of
28 patients. Patients living with human immunodeficiency virus, renal disease or diabetes (4/133;
29 4/133; 3/133) had an increased frequency of unfavourable outcome ($p < 0.05$), but the numbers
30 were small. Among all 133 DR-TB patients, 41% had a low lymphocyte count, which was significantly
31 associated with unfavourable outcome ($p < 0.05$). We noted a 50% increase in successful outcomes
32 achieved in the 2016 - 2020 programmatic period, compared to earlier periods (OR 5.3, 95%
33 Confidence Interval [1.3, 20.4]). Being a close contact of a known TB case was associated with
34 improved outcome.

35 While DR-TB treatment outcomes have improved over time, enhanced surveillance for DR-TB, better
36 cross border collaboration and consistent diagnosis and management of comorbidities and other risk
37 factors should further improve patient care and outcomes.

38

39

40 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

41 **Introduction:**

42 Drug resistance poses a major threat to global tuberculosis (TB) control, with nearly half a million of
43 the ten million cases in 2019 estimated to be rifampicin resistant (1). Drug-resistant (DR)-TB refers to
44 TB strains that are resistant to any of the first-line drugs used to treat fully-susceptible TB, any of the
45 second-line drugs used to treat DR-TB, or are resistant to a combination of these drugs (2).


46 Inadequate adherence to TB treatment may lead to the development of DR-TB and multidrug-
47 resistant (MDR)-TB; resistant to both isoniazid and rifampicin and substantially more difficult and
48 costly to treat (3). Treatment outcomes are generally worse for DR-TB cases due to the use of less
49 potent drugs, prolonged treatment regimens, difficult adherence and potential severe drug-related
50 adverse effects (4). Globally, the average treatment success rate in patients with MDR-TB in 2018
51 was 59% (5), although this is highly variable across countries (Ukraine – 18.1% (6); China – 52.2% (7);
52 Ethiopia – 78.6%) (8).

53 TB control poses an ongoing public health challenge in the Torres Strait / Papua New Guinea (PNG)
54 region. The challenge is compounded by high levels of DR-TB in the Western Province of PNG and in
55 particular, on Daru Island (9, 10) (Fig 1). In 2016, the estimated incidence rate of TB in PNG was 432 /
56 100,000 population (WHO, 11); 674 / 100,000 in the Western Province (12). By comparison, the
57 incidence rate of TB over the border in Queensland, Australia is 5.5 / 100,000 population (13). In the
58 Torres Strait Islands, 80% of people identify as Torres Strait Islander Indigenous peoples (14).
59 Indigenous Australians are disproportionately affected by TB when compared to non-Indigenous
60 Australians (15). It is important to appreciate that residents from specific islands in the Torres Strait
61 and villages in the Western Province of PNG share an open international border (Fig 1), heightening
62 cross-border TB transmission risk (10).

63

64

65 **Fig 1. Map of the Torres Strait / Papua New Guinea cross-border region (16)¹ CC BY 4.0**



66

67 ¹International travel without passport or visa is permitted for traditional inhabitants of the Torres

68 Strait Protected Zone and Treaty villages of Papua New Guinea, DOI. 10.6084/m9.figshare.16632823

69 Management of DR-TB is complex and is often further complicated by comorbidities with other
70 communicable and non-communicable diseases (17). Patients with TB and comorbidities such as
71 renal impairment, diabetes and human immunodeficiency virus (HIV) are more likely to have
72 unfavourable outcomes and are known causes of TB reactivation (18-20). While the rise in DR-TB is a
73 global concern, TB programs must consider specific local risk factors and programmatic gaps to
74 ensure better outcomes for patients. These considerations may present important opportunities for
75 TB programmes to meet the challenging END TB targets, aiming to reduce the incidence of TB by
76 90% before 2035 (21).

77 The aim of this study was to evaluate variables associated with unfavourable outcome and the
78 impact of programmatic changes to models of TB care over time with treatment outcomes in DR-TB
79 patients diagnosed in the Torres Strait / PNG border region. It is the intention that evidence derived
80 from this study will be carefully considered at a programmatic level to further improve outcomes for
81 patients diagnosed with DR-TB in this context.

82 **Methods:**

83 **Study Design and Population**

84 We performed a retrospective cohort study of all patients diagnosed with laboratory-confirmed DR-
85 TB between 2000 and 2020 in the Torres Strait Islands, Australia. Pulmonary, extrapulmonary, smear
86 positive and smear negative cases were included, as well as those with mono (isoniazid, rifampicin or
87 streptomycin mono-resistance), poly (resistant to two or more TB drugs) and MDR-TB (resistant to
88 isoniazid and rifampicin). Streptomycin mono-resistance was included, given the high prevalence
89 reported in parts of PNG (22). Ethionamide resistance was analysed in relation to MDR-TB cases,
90 given reports of frequent isoniazid and ethionamide co-resistance amongst MDR-TB strains
91 circulating on Daru Island (23, 24).

92 Patients were excluded from the study if they were residents of PNG villages external to the Western
93 Province of PNG who did not enter the Australian health system via a health facility in the Torres
94 Strait Protected Zone (Fig 1).

95 ***Models of TB Care – Diagnosis and Treatment***

96 There were four models of TB care provided in the region during the study period, over different
97 periods of time (2000-2005; 2006-2012; 2013-2015; 2016-2020) (25). Supplementary material
98 associated with the models of TB care in this region are available online from
99 <https://doi.org/10.6084/m9.figshare.16834648.v1>. Across all four models of TB care, the primary
100 mode of diagnosis was via sputum collection. Appropriate specimens for the diagnosis of
101 extrapulmonary TB were rarely collected in these remote Australian border clinics. Mycobacterial
102 culture, phenotypic drug susceptibility testing and genotyping were available throughout the study
103 period and were performed on at least one specimen per patient in the Queensland Mycobacterium
104 Reference Laboratory in Brisbane (Fig 1) (24). The major differences in care resulting from these
105 changes were reduction in time to treatment commencement and retention in care (26).

106 Between 2000 and 2012, some treatment for DR-TB was available for PNG nationals diagnosed with
107 DR-TB in Australian border clinics, however, access to treatment was improved between 2006 and
108 2012 with the establishment of frequent outreach TB clinics in the Torres Strait. The change from the
109 2000-2005 model of TB care to the 2006-2012 model of TB care was in direct response to Australian
110 Government decisions to invest in TB management of PNG patients from two outer Torres Strait
111 Islands, Boigu and Saibai (27). The 2013-2015 model of TB care is reflective of Government decisions
112 to stand-down these outer island clinics and increase support and funding for TB health services on
113 the PNG side of the border (28). As a result, PNG residents diagnosed from 2013 onwards were
114 referred back to the PNG health system for treatment and management. Government decisions to
115 invest in a local Torres Strait-based TB Control Unit with the aim to more rapidly and appropriately

116 respond to presumed TB and confirmed DR-TB cases occurred from 2016, and is ongoing (29). All
117 Australian residents in this study were managed within the Australian public healthcare system.

118 ***Data Collection***

119 The Queensland Health's Notifiable Conditions System (NoCS) was used as the source for TB
120 notification data. Only cases with laboratory confirmed DR-TB were included in the study. We used
121 Queensland Health's laboratory software (AUSLAB) as cross-reference. One case was added to the
122 study where their drug-resistant status was identified in AUSLAB, but not registered in NoCS.

123 Relevant biomarker data (haemoglobin, albumin, lymphocyte levels) were obtained from AUSLAB.
124 Routinely collected biomarker data were analysed, but the fact that it was not consistently available
125 in all patients may have introduced some selection bias.

126 The management of DR-TB at the Torres Strait / PNG border presents challenges as it involves
127 patients from two countries accessing health systems on both sides of the border in a very remote
128 geographical location. Given the level of interaction between inhabitants, and the increased risk of
129 DR-TB transmission in this cross-border region (9, 10), outcomes for patients with DR-TB from both
130 sides of the border needed to be considered to evaluate the management of DR-TB in this complex
131 context. Hence, the main strength of this study lies in the linkage and analysis of different data
132 sources. Data from the Queensland Department of Health sources (NoCS and AUSLAB) and the local
133 electronic patient information system used in the Torres Strait called 'Best Practice' were linked to
134 obtain detailed information for each patient included in this study. This data linkage resulted in a
135 more comprehensive insight into the management of DR-TB in the region.

136 ***Definitions***

137 In this study, we used WHO definitions (31), where unfavourable treatment outcome was defined as
138 death, lost to follow up or treatment failure. Successful treatment outcome was defined as
139 completed treatment or cured. Transferred out, indicated that the patient was referred back to the

140 PNG health care system. In some patients that were transferred out, treatment outcome was
141 unknown.

142 Comorbidities were defined as HIV infection, diabetes and renal impairment. Patients with
143 comorbidities recorded as renal dysfunction, renal insufficiency, renal disease and renal failure were
144 all defined as having renal impairment.

145 With reference to haemoglobin levels, anaemia was defined as those with a Z score at least 2
146 standard deviations (SD) away from the mean, and severe anaemia was defined as those with a Z
147 score that was at least 5SD away from the mean. This resulted in our definition of anaemia fitting
148 with the laboratory definition of below the reference range, for a given laboratory and patient
149 profile. Within laboratory software AUSLAB, the result is documented in an orange-coloured if it is at
150 least 2SD away from the mean (anaemia) and in a red-colour if at least 5SD away from the mean
151 (severe anaemia) (32). Similarly, low albumin and lymphocyte levels were defined as those with a Z
152 score at least 2SD away from the mean.

153 **Data Analyses**

154 Statistical analyses were performed using IBM SPSS Statistics, version 25 (2019, Armonk, New York,
155 United States). Frequencies and percentages were calculated for descriptive data including age
156 categories, sex, country of birth, visa status, primary health centre (PHC) attended, programmatic
157 diagnosis year group, site of disease, case type, comorbidities, drug resistance, cough and known
158 close contact status. Pearson's Chi-squared tests were carried out to assess whether age group, sex,
159 country of birth, visa status, and PHC attended were associated with unfavourable treatment
160 outcomes.

161 Potential categorical predictors (site of disease, HIV infection status and comorbidities, case type,
162 drug resistance and selected biomarkers including haemoglobin, lymphocytes and albumin), were
163 analysed by unfavourable, successful or unknown treatment outcome using Fisher's exact or

164 likelihood ratios, except for ethionamide resistance and lymphocyte levels where Pearson Chi-
165 Square was used to ascertain if there was a statistically significant association between these factors
166 and treatment outcomes. Likelihood ratios were used to assess the association between
167 unfavourable treatment outcome and more than one categorical variable. The categorical variable
168 'diagnostic year group' was included in the analysis as a clinical covariate to account for
169 programmatic changes in the clinical management of TB over time.

170 In all univariate and multivariate logistic regression analyses, multiple imputation was applied and
171 pooled results from five imputations were used as 19 DR-TB cases did not have any biomarker
172 results available. Biomarker Z scores were imputed for incomplete variables and were further
173 defined as nominal (unfavourable or other) prior to imputation. To overcome differences in
174 reference range parameters that were automatically applied by Queensland Health's laboratory
175 software, AUSLAB to biomarker results based on sex and age, Z scores were calculated in Microsoft
176 Excel version 2016.

177 Univariate analysis of comorbidities, diagnosis year group, contact with a known case, biomarkers,
178 acid-fast bacilli (AFB) positivity and rifampicin-resistance were examined as potential predictors of
179 unfavourable outcome using binary logistic regression. All predictor variables were considered for
180 multivariate regression. The regression method was a forward algorithm with entry criteria of $p <$
181 0.05 from the univariate analyses followed by a backward algorithm with back entry criteria of $p >$
182 0.05 . The level of significance was set at $p < 0.05$ for all analyses.

183 ***Ethics***

184 The Far North Queensland Human Research Ethics Committee (HREC) (HREC/17/QCH/74-1157)
185 granted a waiver of consent and use of anonymized data, and approved the study, as did the Chair of
186 James Cook University HREC, (H7380). Further approval was obtained to access case notification
187 data via a Public Health Act application (QCH/36155 – 1157).

188 **Results**

189 In total, we identified 133 DR-TB patients during the study period. There were 22 deaths and one
 190 treatment failure, 16 were lost to follow up and 51 were transferred out. Of the 51 that were
 191 transferred out, 41 had no recorded outcome. As shown in Table 1, Boigu Island PHC received fewer
 192 patients than Saibai Island PHC but had marginally greater treatment success (49% vs 38%). The
 193 median age was 28 years, and patients in the 15-29 years age group were both the largest group and
 194 disproportionately affected by unfavourable treatment outcomes. Of six adults aged ≥ 60 years, 83%
 195 ($n = 5$) had an unfavourable treatment outcome. Being a PNG national rather than an Australian
 196 Torres Strait Islander was highly predictive of unfavourable treatment outcome.

197 **Table 1. Demographic characteristics and treatment outcome of all patients diagnosed with drug-**
 198 **resistant tuberculosis in the Torres Strait Islands between 2000 and 2020**

Demographic characteristic	Treatment Outcome N = 133 (%) [†]						Total	p-value
	Successful		Unfavourable			Transferred Out		
	Cured	Completed	Died	Failed	Lost to follow up			
Age group							0.02	
<5 years	2 (22)	5 (56)	0 (0)	0 (0)	0 (0)	2 (22)	9	
5-14 years	1 (10)	3 (30)	1 (10)	0 (0)	2 (20)	3 (30)	10	
15-44 years	9 (9)	30 (32)	15 (16)	0 (0)	14 (15)	27 (28)	95	
45-59 years	0 (0)	2 (15)	2 (15)	0 (0)	0 (0)	9 (70)	13	
≥ 60 years	1 (17)	0 (0)	4 (67)	1 (17)	0 (0)	0 (0)	6	
Sex							0.7	
Female	9 (12)	22 (30)	14 (19)	1 (1)	8 (11)	21 (28)	75	
Male	4 (7)	18 (31)	8 (14)	0 (0)	8 (14)	20 (35)	58	
Country of Birth							0.02	
Australia	3 (50)	2 (33)	1 (17)	0 (0)	0 (0)	0 (0)	6	
Papua New Guinea	10 (8)	38 (30)	21 (17)	1 (1)	16 (13)	41 (32)	127	
Visa Status							0.002	
Australian resident	3 (33)	3 (33)	2 (22)	1 (11)	0 (0)	0 (0)	9	

Papua New Guinea Treaty Visitor	5 (6)	23 (27)	15 (17)	0 (0)	13 (15)	30 (35)	86	
Papua New Guinea non-Treaty Visitor	5 (13)	14 (37)	5 (13)	0 (0)	3 (8)	11 (29)	38	
Primary Health Centre Attended								1.0
Saibai Island	11 (10)	32 (29)	19 (17)	1 (1)	14 (13)	33 (30)	110	
Boigu Island	2 (13)	7 (44)	2 (13)	0 (0)	2 (13)	3 (19)	16	
Murray Island	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	2	
Darnley Island	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	1 (50)	2	
Yorke Island	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)	1 (50)	2	
Thursday Island	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	1	

199 † Percentages may not equal 100 due to rounding.

200

201 Table 2 shows that DR-TB patients diagnosed between 2000 and 2005 were more likely to have
 202 unfavourable treatment outcomes (50%; $n = 7$) than those diagnosed between 2016 and 2020 (17%;
 203 $n = 2$). Overall, outcome improved in recent years with a 50% increase in the chance of a successful
 204 outcome between 2016 – 2020, when compared to all other programmatic year groups; OR 5.3, 95%
 205 Confidence Interval (CI) [1.3, 20.4]. Of 133 DR-TB cases, 67% ($n = 89$) had MDR-TB and of those, 74%
 206 ($n = 66$) were new cases and 32% had an unfavourable treatment outcome. Ethionamide resistance
 207 was only identified in patients diagnosed with MDR-TB ($p < .001$); 90% ($n = 80$) of MDR-TB cases were
 208 found to be ethionamide resistant. Nearly one in five patients had previously received full or partial
 209 treatment in Australia or PNG. The composite comorbidity variable comprised of nine patients with
 210 DR-TB and HIV infection, diabetes and/or renal impairment. Of four patients with DR-TB/HIV
 211 coinfection, and three patients with DR-TB/diabetes comorbidity, none had a successful outcome.
 212 Overall, 78% ($n = 7$) of patients with DR-TB and at least one comorbidity had an unfavourable
 213 treatment outcome.

214

215 **Table 2. Clinical variables of patients diagnosed with drug-resistant tuberculosis in the Torres**
 216 **Strait between 2000 and 2020, and their association with successful, unfavourable and other TB**
 217 **treatment outcome**

Variable	Treatment Outcome N = 133 (% of total)			Total	p-value
	Unfavourable (N = 39; 29%)	Successful (N = 53; 40%)	Transferred out (N = 41; 31%)		
Diagnosis Year Group*^				133	0.045
2000-2005	7 (50)	5 (36)	2 (14)	14	
2006-2012	26 (27)	37 (39)	33 (34)	96	
2013-2015	4 (36)	2 (18)	5 (46)	11	
2016-2020	2 (17)	9 (75)	1 (8)	12	
Disease Site				133	0.08
Pulmonary TB	25 (34)	22 (30)	26 (36)	73	
Extrapulmonary TB	2 (20)	7 (50)	1 (10)	10	
Both PTB and EPTB	12 (24)	24 (48)	14 (28)	50	
Cavitary Disease	16 (42)	12 (32)	10 (26)	38	0.1
Case Type				133	0.2
New	29 (27)	41 (38)	37 (35)	107	
Full or partial treatment overseas	8 (38)	11 (52)	2 (10)	21	
Full or partial treatment in Australia	2 (40)	1 (20)	2 (40)	5	
Comorbidities				133	0.003
Diabetes Mellitus, Renal Disease or HIV infection	7 (78)	0	2 (22)	9	
No known risk factors	32 (26)	53 (43)	39 (32)	124	
Drug Resistance				133	0.04
Isoniazid (mono)	5 (14)	16 (46)	14 (40)	35	
Rifampicin (mono)	3 (75)	1 (25)	0	4	
MDR-TB	29 (33)	33 (37)	27 (30)	89	
Other (streptomycin mono)	2 (40)	3 (60)	0	5	
Ethionamide				133	0.8
Ethionamide resistant	24 (30)	30 (38)	26 (33)	80	
Susceptible	15 (28)	23 (43)	15 (28)	53	
Cough				114	0.1
Cough	27 (31)	31 (36)	29 (33)	87	
No cough	4 (15)	15 (56)	8 (30)	27	
Close Contact[#]				133	0.02
Close contact	8 (16)	23 (45)	20 (39)	51	
No known contact	31 (38)	30 (37)	21 (26)	82	

218 Note. Unfavourable treatment outcome - died, failed, lost to follow up; successful outcome - cured,
219 completed treatment; other - transferred out

220 *Diagnosis year group was included as a variable due to changes in the clinical management of DR-
221 TB patients over time.

222 ^OR 5.3, 95% CI [1.3, 20.4], where diagnostic year group 2016-2020 versus all other year groups was
223 analysed as a categorical variable by successful treatment outcome versus unfavourable treatment
224 outcome or transferred out

225 #Close contact to a known TB case as reported by patient.

226 PTB, pulmonary TB; EPTB, extrapulmonary TB; MDR-TB, multidrug-resistant TB.

227

228 Table 3 shows that 86% ($n = 92$) of patients with haemoglobin recorded had anaemia, and of those,

229 38% ($n = 35$) had severe anaemia. Low albumin was detected in 76% ($n = 80$) of patients, where this

230 was measured. A large percentage of patients with low lymphocyte levels, (44%; $n = 43$) had an

231 unfavourable treatment outcome.

232 **Table 3. Blood test abnormalities in patients diagnosed with drug-resistant tuberculosis in the**
233 **Torres Strait between 2000 and 2020, and their association with treatment outcome**

Variable	Treatment Outcome n (%)			
	Unfavourable	Other	Total	p-value
Haemoglobin Levels* (50-146L)			107	0.5
No anaemia	3 (20)	12 (80)	15	
Mild anaemia	20 (35)	37 (65)	57	
Severe anaemia	10 (29)	25 (71)	35	
Lymphocyte count# (0.04-9.80L)			106	0.01
Normal	13 (21)	50 (79)	63	
Low	19 (44)	24 (56)	43	
Albumin# (<15-48L)			105	0.07
Other (normal or high)	4 (16)	21 (84)	25	
Low	28 (35)	52 (65)	80	

234 *Mild anaemia, at least 2 standard deviations (SD) away from the mean; severe anaemia, at least

235 5SD away from the mean; #Low lymphocyte and albumin, at least 2SD away from the mean.

236 In Table 4, patients with comorbidities, low lymphocyte levels and AFB positivity were significantly

237 more likely to have unfavourable treatment outcomes. Being a close contact of a known TB case was

238 a protective factor and reduced the odds of an unfavourable treatment outcome occurring (p .008;
239 OR .31). Although the p value for anaemia in Table 3 was $> .1$, this variable was included in the
240 univariate analysis as other studies have demonstrated an association between anaemia and
241 unfavourable treatment outcomes (33), however in this study, anaemia was not a significant
242 predictor of unfavourable treatment outcomes. In the adjusted multivariate model, comorbidities,
243 being a close contact of a known TB case and low lymphocyte levels retained significance ($p < 0.05$).

244 **Table 4. Variables associated with unfavourable treatment outcome among drug-resistant**
245 **tuberculosis cases diagnosed in the Torres Strait / Papua New Guinea border region between 2000**
246 **and 2020 (N = 133)**

Variable		Unfavourable outcome	Univariate Analysis		Multivariate Analysis	
	n (%)	n (%)	OR (95% CI)	p-value	aOR (95% CI)	p-value
Comorbidities (DM, renal, HIV infection)	9 (7)	7 (78)	10.06 (1.98-50.96)	0.005	17.4 (2.6-117.06)	0.003
Contact with known TB case	51 (38)	8 (16)	.3 (.12-.73)	0.008	.3 (.08-.87)	0.03
Low lymphocyte level	43 (32)	19 (44)	3.05 (1.29-7.17)	0.01	2.7 (1.1-7.08)	0.04
AFB positive	80 (60)	29 (36)	2.4 (1.07-5.58)	0.03	1.6 (.56-4.48)	0.4
Rifampicin resistance	93 (70)	32 (34)	2.5 (.96-6.21)	0.05	Eliminated at forward step	
Anaemia	93 (70)	30 (32)	1.9 (.50-7.26)	0.3	Eliminated at forward step	
Low albumin level	80 (60)	28 (35)	2.8 (.88-9.05)	0.08	Eliminated at forward step	
Female sex	75 (56)	23 (31)	1.2 (.55-2.47)	0.7	Eliminated at forward step	

247 Note. aOR, adjusted odds ratio; CI, confidence interval; DM, diabetes mellitus; renal, renal
248 impairment; HIV, human immunodeficiency virus; AFB, acid-fast bacilli.

249

250 Discussion

251 Few reports focus on the specific challenges and unique health care access issues experienced by
252 DR-TB patients in remote settings like the Torres Strait / PNG border region. This study identified
253 variables associated with unfavourable treatment outcomes in patients diagnosed with DR-TB and

254 examined the impact of four different models of TB care over two decades. We documented a
255 significant improvement in successful treatment outcomes once a local decentralised TB control unit
256 was established in 2016. Patients diagnosed before 2013 had the worst treatment outcomes, which
257 is reflective of a time when accessibility to mycobacterial culture and drug susceptibility testing was
258 not routinely available on Daru Island in PNG, and where access to second-line TB drugs was only
259 available for Western Province PNG nationals via Australian TB clinics (34). For patients diagnosed
260 between 2013 and 2015 in this study, a higher proportion had an unknown outcome. This is
261 consistent with the changeover from the 2006 to 2012 TB management model of increased
262 surveillance and detection at border clinics, to a handover period whereby PNG patients diagnosed
263 at Australian border health facilities were referred back to the PNG health system for ongoing
264 management and care.

265 From 2016 onwards, TB clinicians were based in the Torres Strait and therefore able to rapidly
266 respond to cases diagnosed, associated contact tracing efforts and monitoring of treatment
267 compliance and outcomes for patients. Higher success rates for DR-TB patients have been reported
268 in countries where patients have access to developed health infrastructure and where skilled
269 clinicians are positioned to support DR-TB patients (35). From 2016, local nurses and Indigenous
270 Health Workers undertook Directly Observed Therapy for TB patients residing in the Torres Strait.
271 Collegial relationships between TB programs in the Torres Strait and Daru Island were also
272 strengthened through this period with the joint development of procedural documents and
273 processes (36) which enabled each TB program to define data requirements, streamline the
274 exchange of shared patient information, and enhance surveillance capability. These strengthened
275 relationships may help to explain the reduction in unknown treatment outcomes in this study from
276 2016. These initiatives are consistent with the Australian National Tuberculosis Advisory Committee
277 (NTAC) recommendations to engage in regional and bilateral collaborations in order to improve TB
278 services in cross-border areas (37).

279 It is widely accepted that household contacts of DR-TB patients are at greater risk of exposure,
280 infection and disease progression when compared with other types of contacts (38). In a study of
281 MDR-TB index cases in Pakistan, MDR-TB diagnoses were reported in 17.4% of close contacts (38).
282 Unlike isoniazid-resistant TB which is more amenable to treatment, patients with MDR-TB may be
283 more likely to remain infectious longer than patients with drug susceptible TB (39), thus increasing
284 the likelihood of transmission to close contacts. Despite the increased transmission risk, close
285 contacts had more favourable outcomes in this study. A possible explanation is that these close
286 contact patients were actively screened, or linked in with healthcare services earlier because of
287 raised awareness, leading to earlier diagnosis and potentially improved treatment adherence. Better
288 outcomes for close contacts after 2014 may also be attributed to improved health literacy and
289 symptom recognition as a result of mass community education offered in the region from 2014 (40).

290 This retrospective study has a number of limitations. Details of the drug regimens used for individual
291 patients in this study were not available for analysis, however twice and thrice weekly dosing of
292 second-line drugs was available for some MDR-TB patients treated between 2006 and 2015. From
293 2016, clofazimine and linezolid were included in most MDR-TB regimens in the region per WHO
294 recommendations (41), and bedaquiline was first used in the region in 2018. The study did not
295 identify the type of close contact (i.e. household contact), nor ascertain the type of TB that each
296 close contact was exposed to. The recent upgrade of the Mabadauan health centre in PNG will aid
297 the PNG health system's capacity to manage close contacts in border communities. It will, however,
298 be important that expanded diagnostic capabilities at Mabadauan, are matched with capacity to
299 retain patients in the TB care pathway (35). Since 2016, the Torres and Cape TB Control Unit has
300 collected and shared TB contact tracing data with Daru General Hospital, related to all PNG residents
301 diagnosed with TB in the Torres Strait. It is anticipated that increased capacity of local health
302 services available to residents of PNG living adjacent to the Torres Strait, may lead to effective TB
303 contact management, further improve treatment outcomes for PNG patients diagnosed with DR-TB
304 as well as support TB patients with other comorbidities.

305 Patients with pre-existing comorbidities in this study were significantly more likely to have
306 unfavourable treatment outcomes, which is consistent with earlier findings (6, 42, 43). In our study,
307 no patients with a serious comorbidity were cured or completed treatment. HIV is a major risk factor
308 for TB disease development and associated with unfavourable treatment outcome in the absence of
309 successful HIV care, which is a major concern in the study setting. However, HIV is unlikely to be a
310 major contributing factor in community TB transmission dynamics as currently less than 1% of the
311 population is HIV infected (44). It is possible that ‘stand-alone’ vertical disease programs for TB
312 control, diabetes management and sexual health, may contribute to poor linkage of care and
313 unfavourable treatment outcomes for DR-TB patients with a comorbidity (45). It would be beneficial
314 for TB programs to establish strong linkages with both diabetes educators and sexual health
315 providers to provide enhanced screening, monitoring and management support for patients with
316 these comorbidities (46). As there were no protocols in place to consistently screen TB patients for
317 diabetes or renal impairment during this study period, it is possible that comorbidities have been
318 under-reported in this study.

319 In renal patients, delayed TB diagnosis is a possible reason for unfavourable outcome (47).
320 Aboriginal and Torres Strait Islander peoples develop chronic kidney disease three times as often as
321 non-Indigenous Australians (48) and in Torres Strait Islander adults, a recent survey found that
322 nearly one in five people showed signs and symptoms of chronic kidney disease (49). Renal
323 impairment is more likely to be documented in residents of the Torres Strait Islands due to their
324 relative ease of access to ongoing health services in the region. By contrast, an absence of renal
325 dialysis in the Treaty villages suggests there would be limited survival of PNG patients with kidney
326 disease. As uremic symptoms like fever and weight loss are non-specific symptoms of both TB and
327 renal disease, renal physicians would be well placed to consider TB as a differential diagnosis and
328 monitor patients with insidious onset of these symptoms (47). Early detection of TB in renal patients
329 may be key to improved outcomes (47). Efforts to increase collaboration between renal and TB units
330 in the Torres Strait may help reduce diagnostic delay and better support shared patients. Many

331 studies have reported high rates of mortality in TB patients with comorbidities (47, 50-52) and in
332 patients with low levels of haemoglobin, albumin and lymphocytes (53).

333 Although not consistently measured, low lymphocyte levels were statistically significantly associated
334 with unfavourable treatment outcomes in DR-TB patients, and also among HIV uninfected patients,
335 which is consistent with findings in other studies (54). In patients who were previously lost to follow
336 up or with past treatment failure, overall health decline evidenced by low lymphocyte levels can be a
337 marker for disease severity and complexity (55). When compared to drug susceptible TB, lower
338 lymphocyte counts have been reported in MDR-TB patients (56). Low lymphocyte counts, as well as
339 haemoglobin and albumin levels, are all indicative of general poor health at the time of treatment
340 initiation.

341 Low haemoglobin and albumin levels have been identified as strong predictors of TB mortality (57)
342 and in China and Israel, an association between hypoalbuminaemia and poor prognosis in DR-TB
343 patients has been reported (7, 58). A study conducted in Ethiopia reported that MDR-TB patients
344 with low haemoglobin levels (anaemia) were more than twice as likely to have unfavourable
345 treatment outcomes when compared to patients without anaemia (42). Low haemoglobin has also
346 been associated with unfavourable treatment outcomes in non-MDR TB patients, specifically with
347 delayed sputum conversion at two months (59). It is possible that the anaemia observed in DR-TB
348 patients is due to nutritional iron deficiency and not chronic disease (33), however this study did not
349 explore levels of iron, ferritin, hepcidin and transferrin in TB patients or assess haemoglobin levels in
350 the general population.

351 Several limitations have already been described above. Another limitation of this study is that only
352 people with laboratory-confirmed DR-TB isolates were included, excluding those with drug
353 susceptible TB or unconfirmed DR-TB. This therefore represents a very select group and limits our
354 ability to comment on general trends and outcomes. We were however able to compare those with

355 and without rifampicin resistance, finding a trend to worse outcome in those with rifampicin
356 resistance.

357 Apart from selection bias, the relatively small number of patients also affected the power of our
358 statistical analyses. Future studies could incorporate drug-susceptible patients as well, which would
359 provide a more generalizable comparator. We were unable to ascertain whether the cause of death
360 for all patients was TB, however, patient death was documented during the time period for the
361 course of TB treatment for all patients. As this was an observational study of care delivered over
362 time, we acknowledge that there may be confounding factors, linked to changes in clinical care and
363 the availability of new diagnostic tools and treatment options.

364 **Conclusion**

365 Although having a locally-based TB program in the Torres Strait has resulted in better treatment
366 outcomes for DR-TB patients, more interventions to improve treatment outcomes and refine the
367 focus on vulnerable sub-populations are needed. Most patients with comorbidities in this study had
368 an unfavourable treatment outcome and poor health indicators suggesting late presentation or
369 underlying poor management of their comorbidity. These findings have important implications for
370 TB programs on both sides of this international border. Key strategies should include strong cross-
371 border working relationships, as well as better collaboration with diabetes, renal and sexual health
372 care providers to identify and manage TB in patients. There should be an ongoing commitment to
373 enhance HIV care and to improve the care of DR-TB patients at-risk of unfavourable treatment
374 outcomes.

375

376

377

378

379 REFERENCES

- 380 1. World Health Organization. Global tuberculosis report. Geneva, Switzerland: World Health
381 Organization; 2020.
- 382 2. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis
383 treatment. Geneva, Switzerland: World Health Organization; 2019.
- 384 3. Jenkins HE, Crudu V, Soltan V, Ciobanu A, Domente L, Cohen T. High risk and rapid
385 appearance of multidrug resistance during tuberculosis treatment in Moldova. *Eur Respir J*.
386 2014;43:1132-41.
- 387 4. Sagwa E, Ruswa N, Musasa JP, Mantel-Teeuwisse AK. Adverse events during treatment of
388 drug-resistant tuberculosis: A comparison between patients with or without human
389 immunodeficiency virus co-infection. *Drug Safety*. 2013;36:1087–96.
- 390 5. World Health Organization. Tuberculosis Geneva, Switzerland: World Health Organization;
391 2021 [Available from: <https://www.who.int/news-room/fact-sheets/detail/tuberculosis#>.
- 392 6. Aibana O, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, Petrenko V, et al. Risk factors for
393 poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. *Biomed Central
394 Infectious Diseases*. 2017;17(129).
- 395 7. Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk Factors for Poor Treatment Outcomes in
396 Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation. *PLoS ONE*.
397 2013;8(12).
- 398 8. Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, et al. Achieving high
399 treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in
400 Ethiopia—an observational cohort study. *Biomed Journal Thorax*. 2015;70(12).
- 401 9. Furin J, Cox H. Outbreak of multidrug-resistant tuberculosis on Daru Island. *Lancet Respir
402 Med*. 2016;4(5):347-9.
- 403 10. Baird T, Donnan, E., Coulter, C., Simpson, G., Konstantinos, A., Eather, G. . Multidrug-
404 resistant tuberculosis in Queensland, Australia: an ongoing cross-border challenge. *Int J Tuberc Lung
405 Dis*. 2018;22(2):206-11.
- 406 11. World Health Organization. TB country profile - Papua New Guinea. Geneva, Switzerland:
407 World Health Organization; 2016.
- 408 12. Aia P, Wangchuk L, Morishita F, Kisomb J, Yasi R, Kal M, et al. Epidemiology of tuberculosis in
409 Papua New Guinea: analysis of case notification and treatment-outcome data, 2008-2016. *Western
410 Pacific Surveillance and Response Journal*. 2018;9(2):9-19.
- 411 13. Viney K. The Australian tuberculosis risk factor survey Canberra, ACT: Australian National
412 University; 2021.
- 413 14. Australian Bureau of Statistics. Changing characteristics of the Torres Strait region and its
414 people. Canberra, ACT: Australian Bureau of Statistics; 2018.
- 415 15. Robertus LM, Konstantinos A, Hayman NE, Paterson DL. Tuberculosis in the Australian
416 indigenous population: History, current situation and future challenges. *Australian and New Zealand
417 Journal of Public Health*. 2011;35(1):6-9.
- 418 16. Moran M, Foster J, Mendez D, cartographers. Map of the Torres Strait / Papua New Guinea
419 cross-border region. Cairns, Queensland; 2021.
- 420 17. Esmail A, Sabur NF, Okpechi I, Dheda K. Table Bloods. Management of drug-resistant
421 tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes,
422 organ-specific dysfunction, and in the critically ill. *Journal of Thoracic Disease*. 2018;10(5).
- 423 18. Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabe-Ortiz A. Mortality among
424 MDR-TB Cases: Comparison with Drug-Susceptible Tuberculosis and Associated Factors. *PLoS ONE*.
425 2015;10(3).
- 426 19. Bhering M, Duarte R, Kritski A. Predictive factors for unfavourable treatment . in MDR-TB and
427 XDR-TB patients in Rio de Janeiro State, Brazil, 2000-2016. *PLoS ONE*. 2019;14(11).
- 428 20. Gómez-Gómez A, Magaña-Aquino M, López-Meza S, Aranda-Álvarez M, Díaz-Ornelas DE,
429 Guadalupe Hernández-Segura M, et al. Diabetes and Other Risk Factors for Multi-drug Resistant

- 430 Tuberculosis in a Mexican Population with Pulmonary Tuberculosis: Case Control Study. Archives of
431 medical research. 2015;46(2).
- 432 21. World Health Organization. WHO End TB Strategy. Geneva: Switzerland: World Health
433 Organization; 2015.
- 434 22. Ley SD, Harino P, Vanuga K, Kamus R, Carter R, Coulter C, et al. Diversity of Mycobacterium
435 tuberculosis and drug resistance in different provinces of Papua New Guinea. Biomed Central
436 Microbiology. 2014;14(307).
- 437 23. Bainomugisa A, Lavu E, Hiashiri S, Majumdar S, Honjepari A, Moke R, et al. Multi-clonal
438 evolution of multi-drug-resistant/extensively drug-resistant Mycobacterium tuberculosis in a high-
439 prevalence setting of Papua New Guinea for over three decades. Microb Genom. 2018;4(2).
- 440 24. Bainomugisa A, Pandey S, Donnan E, Simpson G, Foster J, Lavu E, et al. Cross-border
441 movement of a highly drug resistant Mycobacterium tuberculosis strain identified in the Torres
442 Strait, Australia. Emerging Infectious Disease. 2019;25(3).
- 443 25. Foster J. Clinical management of tuberculosis in the Torres Strait / Papua New Guinea cross-
444 border region between 2000 and 2020. Figshare; 2022.
- 445 26. Foster J, Mendez D, Marais B, Peniyamina D, McBryde ES. Time to commencement of
446 effective treatment in patients with drug-resistant tuberculosis diagnosed in the Torres Strait /
447 Papua New Guinea cross-border region. medRxiv; 2022.
- 448 27. Vincent SD. A clinician's perspective on providing TB services in the Torres Strait. Medical
449 Journal of Australia. 2011;195(9):506-7.
- 450 28. Marais B, Sorrell T, Brittle W. Drug-resistant tuberculosis in PNG and Torres Strait islands.
451 The Conversation. 2012.
- 452 29. Queensland Health. Tuberculosis (TB) Control Unit Brisbane, Queensland: Torres and Cape
453 Hospital and Health Service; 2016 [Available from: [https://www.health.qld.gov.au/torres-
454 cape/html/tuberculosis](https://www.health.qld.gov.au/torres-cape/html/tuberculosis)
- 455 30. Queensland Health. Tuberculosis in Queensland, 2016. Brisbane, Australia: State of
456 Queensland (Queensland Health); 2017.
- 457 31. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 5:
458 Management of tuberculosis in children and adolescents. Geneva, Switzerland: WHO; 2022.
- 459 32. AUSLAB laboratory information system. Pathology Queensland; 2019.
- 460 33. de Mendonça EB, Schmaltz CA, Sant'Anna FM, Vizzoni AG, Mendes-de-Almeida DP, et al.
461 Anemia in tuberculosis cases: A biomarker of severity? PLoS ONE. 2021;16(2).
- 462 34. Simpson G. Multidrug-resistant tuberculosis on Australia's northern border. Intern Med J.
463 2011;41(11):759-61.
- 464 35. Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, et al. Multidrug-resistant
465 tuberculosis around the world: what progress has been made? Eur Respir J. 2015;45(1):150-60.
- 466 36. Torres and Cape Hospital and Health Service. Procedure: Management of Papua New Guinea
467 Nationals accessing healthcare within the Australian Islands of the Torres Strait Protected Zone,
468 presumed to have or diagnosed with tuberculosis. Cairns, Queensland: Torres and Cape Hospital and
469 Health Service; 2017.
- 470 37. National Tuberculosis Advisory Committee. The Strategic Plan for Control of Tuberculosis in
471 Australia, 2016–2020: Towards Disease Elimination. The National Tuberculosis Advisory Committee
472 for the Communicable Diseases Network Australia Communicable Diseases Intelligence.
473 2018;2019(43):1-19.
- 474 38. Javaid A, Khan MA, Khan MA, Mehreen S, Basit A, Khan RA, et al. Screening outcomes of
475 household contacts of multidrug-resistant tuberculosis patients in Peshawar, Pakistan. Asian Pacific
476 Journal of Tropical Medicine. 2016;9(9):909-12.

- 477 39. Khan MA, Mehreen S, Basit A, Khan RA, Jan F, Ullah I. Characteristics and treatment
478 outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar,
479 Pakistan. *Saudi Medical Journal*. 2015;36(12):1463.
- 480 40. Torres and Cape Hospital and Health Service. TB education in PNG treaty villages. Cairns,
481 Queensland; 2015.
- 482 41. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis.
483 Geneva, Switzerland: WHO; 2016.
- 484 42. Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements ACA. Treatment outcomes in patients
485 with multidrug-resistant tuberculosis in north-west Ethiopia. *Tropical Medicine & International*
486 *Health*. 2016;22(3):351-62.
- 487 43. Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on
488 tuberculosis treatment outcomes: A systematic review. *BioMed Central Medicine*. 2011;9(81).
- 489 44. Viney K, O'Connor J, Wiegandt A. The epidemiology of tuberculosis in pacific island countries
490 and territories: 2000-2007. *Asia Pac J Public Health*. 2011;23(1):86-99.
- 491 45. Bates M, Marais BJ, Zumla A. Tuberculosis Comorbidity with Communicable and
492 Noncommunicable Diseases. *Perspectives in Medicine*. 2015;11(6).
- 493 46. Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P, et al. Tuberculosis
494 comorbidity with communicable and non-communicable diseases: integrating health services and
495 control efforts. *Lancet Infect Dis*. 2013;13:436-48.
- 496 47. Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and Chronic Renal Disease. *Seminars in*
497 *Dialysis*. 2003;16(1):38-44.
- 498 48. Australian Department of Health. What we're doing about kidney disease Canberra,
499 Australia: Australian Department of Health; 2020 [Available from:
500 [https://www.health.gov.au/health-topics/chronic-conditions/what-were-doing-about-chronic-](https://www.health.gov.au/health-topics/chronic-conditions/what-were-doing-about-chronic-conditions/what-were-doing-about-kidney-disease)
501 [conditions/what-were-doing-about-kidney-disease](https://www.health.gov.au/health-topics/chronic-conditions/what-were-doing-about-kidney-disease).
- 502 49. Australian Institute of Health and Welfare. Profiles of Aboriginal and Torres Strait Islander
503 people with kidney disease. Canberra, Australia: Australian Institute of Health and Welfare; 2020.
504 Report No.: 978-1-76054-712-7 Contract No.: Cat. no: IHW 229.
- 505 50. Lui SL, Tang S, Li FK, Choy BY, Chan TM, Lo WK, et al. Tuberculosis infection in Chinese
506 patients undergoing continuous ambulatory peritoneal dialysis. *American Journal of Kidney Disease*.
507 2001;38:1055-60.
- 508 51. Taskapan H, Utas C, Oymak FS, Gulmez I, Ozesmi M. The outcome of tuberculosis in patients
509 on chronic hemodialysis. *Clinical Nephrology*. 2000;54:134-7.
- 510 52. Moore DA, Lightstone L, Javid B, Friedland JS. High rates of tuberculosis in end-stage renal
511 failure: the impact of international migration. *Emerging Infectious Disease*. 2002;8:77-8.
- 512 53. Rarau P, Guo S, Baptista SN, Pulford J, McPake B, Oldenburg B. Prevalence of non-
513 communicable diseases and their risk factors in Papua New Guinea: A systematic review. *SAGE Open*
514 *Medicine*. 2020;8.
- 515 54. Chedid C, Kokhreizdec E, Tukvadze N, Banud S, Khaja M, Uddind M, et al. Association of
516 baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered
517 cohort study. *International Journal of Infectious Diseases*. 2020;100:199-206.
- 518 55. Panteleev AV, Nikitina IY, Burmistrova IA, Kosmiadi GA, Radaeva TV, Amansahedov RB, et al.
519 Severe Tuberculosis in Humans Correlates Best with Neutrophil Abundance and Lymphocyte
520 Deficiency and Does Not Correlate with Antigen-Specific CD4 T-Cell Response. *Frontiers in*
521 *Immunology*. 2017;21(8):963.
- 522 56. Kiran B, Cagatay T, Clark P, Kosar F, Cagatay P, Yurt S, et al. Can immune parameters be used
523 as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis?
524 *Archives of Medical Science*. 2010;6(1):77-82.
- 525 57. Mehta JB, Fields CL, Byrd Jr RP, Roy TM. Nutritional status and mortality in respiratory failure
526 caused by tuberculosis. *Journal of the Tennessee Medical Association*. 1996;89(10):369-71.

- 527 58. Bendayan D, Hendler A, Polansky V, Weinberger M. Outcome of hospitalized MDR-TB
528 patients: Israel 2000–2005. *European Journal of Clinical Microbiology and Infectious Diseases*.
529 2011;30:375-9.
- 530 59. Nagu TJ, Spiegelman D, Hertzmark E, Aboud S, Makani J, Matee MI, et al. Anemia at the
531 Initiation of Tuberculosis Therapy Is Associated with Delayed Sputum Conversion among Pulmonary
532 Tuberculosis Patients in Dar-es-Salaam, Tanzania. *PLoS ONE*. 2014;9(3).

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

